Recognizing the specific need for a dual system that allows immunogenic cell killing and a reliable kill switch in cancer cell–based immunotherapies, we developed and evaluated an inducible RIPK3-driven necroptotic suicide system using a whole tumor cancer cell vaccine as a therapeutic to treat glioblastoma (GBM). This evidence concerns the gene RIPK3 and glioblastoma.